Resources
2 Results (showing 1 - 2)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 7/6/2020 (updated 3/28/2024)
This toolkit was produced by the University of Minnesota Rural Health Research Center, in partnership with the NORC Walsh Center for Rural Health Analysis, and in collaboration with the Rural Health Information Hub (RHIhub).